Research comparing quality of cancer care by insurance categories concluded that cancer patients without insurance or with Medicaid experienced inferior quality of care compared with those with private insurance.
egory created from the Affordable Care Act (ACA) is insurance purchased from the Health Insurance Marketplace (also known as the exchange). The present study provides empirical investigations of the quality of cancer care under the ACA by examining patterns of radiation therapy (RT) following breast-conserving surgery (BCS), an important quality of care indicator for breast cancer. 3 Methods | We used 2014 Health Care Cost Institute (HCCI) (http://www.healthcostinstitute.org/) deidentified data, a commercial claims database covering 50 million insured individuals per year. The study was exempt for approval by the institutional review board at The University of Texas MD Anderson Cancer Center for the use of deidentified data. In November 2016, the HCCI released a new variable for 2014 data that allowed identification of individuals insured through an exchange, creating an unprecedented opportunity to understand quality of care received by this group. We identified our study cohort as breast cancer patients who received BCS after obtaining insurance through an exchange or other private insurance and had no mastectomy within 6 months of BCS, and constructed 1-to-2 case-control cohort (matched by age group and state of residence). To determine whether a patient received RT within 6 months of BCS, a minimum of 6 months of continuous enrollment since BCS was required to ensure complete information. We compared rate of RT and distribution of time to RT initiation (TTI) between the exchange and nonexchange groups using χ 2 and log-rank test, respectively.
We employed logistic regression and Cox proportional hazards regression model that accounted for paired data structure to determine factors (covariates see Table) associated with RT use and TTI, respectively. We performed sensitivity analyses on a 1-to-3 matched cohort.
Results | The study cohort included 279 breast cancer patients (93 in the exchange group). Approximately 60% of patients were ≥ age 55 and the primary insurance holder (72.4%). The unadjusted rate of RT was similar between the exchange and nonexchange groups (64.5% vs 66.1%, P = .79) (Table) . Logistic regression showed that the likelihood of receiving RT did not differ by whether the insurance was obtained through the exchange (odds ratio = 0.89, 95% CI, 0.49-1.63). No statistically significant difference in distribution of TTI was found between the exchange and nonexchange groups both in the univariate (median TTI 63 vs 74 days, P = .98) and multivariable analysis (hazard ratio [HR]: 1.17, 95% CI, 0.78-1.75) ( Figure) . The only significant predictor of TTI was chemotherapy (HR 0.30; 95% CI, 0.15-0.54). Sensitivity analysis showed similar patterns.
Discussion | Our analysis showed breast cancer patients in the exchange group had quality of care similar to those in the nonexchange group, as indicated by similar rate of RT and TTI between the two groups. BCS patients should be comparable between these two groups as comparisons of surgery type by exchange status showed similar rate of BCS. Our finding implies that the ACA has exerted its intended effect to improve the quality of care for breast cancer patients who would otherwise be uninsured or underinsured without purchasing insurance acquired through the exchange. The lower rate of RT reported here likely reflected a shorter time window employed to identify RT and a relatively younger study cohort as research has shown a lower RT rate among younger women. 4 An important data limitation is the lack of information on race/ ethnicity, which is known to be associated with RT use. 5 Future policies to replace the ACA should ensure that any transitioning plans will not jeopardize the access, continuity, and quality of care and will further expand accessibility to patients who remain uninsured or underinsured. 
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Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals
To the Editor Petrelli and colleagues 1 examined the prognostic role of left-vs right-sidedness of primary colon cancer by a systematic review and meta-analysis and found that tumors on the right side were associated with significantly higher risk of death. They proposed incorporating colon cancer sidedness as a criterion for establishing prognosis when deciding oncologic treatment intensity in the adjuvant and metastatic settings. Whereas their findings were robust and bear important implications for oncologists, they could also be generalized to primary care practitioners and endoscopists. Their findings could contribute to at least 3 additional areas of clinical practice, including risk-based screening, prioritization of diagnostic colonoscopy, and colonoscopy surveillance intervals. Currently, colonoscopy and fecal immunochemical tests are recommended by the US Preventive Services Task Force as primary screening tests for colorectal cancer. 2 Findings by Petrelli and colleagues 1 reinforce the importance of high-quality colonoscopy because postcolonoscopy colorectal cancers are more likely to be from the proximal colon. They also have implications for fecal immunochemical test-based programmatic screening. Because fecal immunochemical testing has low sensitivity for sessile serrated lesions, which are increasingly recognized as precursors to colorectal cancer with CpG island methylation and BRAF mutation, which are predominantly along the proximal colon, patients at higher risk for these lesions should perhaps be considered for colonoscopy screening instead. This however calls for more precise synthesis of validated tools 3,4 that estimate colonic neoplasia on the right side. The use of algorithms to predict lesions on the right side may also be considered by clinicians when symptomatic patients are triaged to receive routine vs early colonoscopy, based on risk prediction tools for proximal neoplasia. 3, 4 In addition, current guidelines recommend surveillance colonoscopy in 5 to 10 years and less than 3 years, respectively, after index findings of low-risk and high-risk adenomas, but do not take into 
